The great wall: why overseas sponsors are yet to fully tap into China’s clinical trial resources
China is an attractive study destination, yet our data-driven analysis shows the country’s clinical trial industry is still insular. Clinical…
By
China is an attractive study destination, yet our data-driven analysis shows the country’s clinical trial industry is still insular. Clinical…
ByGowri Sukumar, ESSA Pharmaceuticals, talks to CTA’s Henry Kerali about the challenges of manufacturing IMPs for clinical trials